Effects of low molecular weight Heparin sodium combined with Labetalol in treatment of patients with gestational hypertension
Objective:To observe effects of low molecular weight Heparin sodium combined with Labetalol in treatment of patients with pregnancy-induced hypertension (PIH). Methods:The clinical data of 66 patients with PIH admitted to the hospital from May 2019 to July 2023 were retrospectively analyzed. According to different treatment methods,they were divided into control group and study group,33 cases in each group. Both groups were given routine treatment. On this basis,the control group was treated with Labetalol,while the study group was treated with low molecular weight Heparin sodium on the basis of that of the control group. The clinical efficacy,the blood pressure (systolic blood pressure,diastolic blood pressure),the serological indexes[placental growth factor (PLGF),hypoxia-inducible factor-α (HIF-α),homocysteine (Hcy)]levels before and after the treatment,the incidence of adverse pregnancy outcomes,and the incidence of adverse reactions were compared between the two groups. Results:The total effective rate of the study group was 93.94％ (31/33),which was higher than 75.76％ (25/33) of the control group,and the difference was statistically significant (P<0.05). After the treatment,the levels of systolic blood pressure and diastolic blood pressure in the two groups were lower than those before the treatment,those in the study group were lower than those in the control group,and the differences were statistically significant (P<0.05). After the treatment,the levels of PLGF in the two groups were higher than those before the treatment,and that in the study group was higher than that in the control group;the levels of HIF-α and Hcy in the two groups were lower than those before the treatment,and those in the study group were lower than those in the control group;and the differences were statistically significant (P<0.05). The incidence of adverse pregnancy outcomes in the study group was lower than that in the control group,and the difference was statistically significant (P<0.05). However,there was no significant difference in the incidence of adverse reactions between the two groups (P>0.05). Conclusions:Low molecular weight Heparin sodium combined with Labetalol in the treatment of the PIH patients can improve the total effective rate of treatment,reduce the blood pressure levels and the incidence of adverse pregnancy outcomes,and improve the levels of serological indexes. Moreover,it is superior to simple Labetalol treatment.
万方数据
维普
